Short answer
Cytek Biosciences, Inc. (CTKB) filed an 8-K current report with the SEC on August 24, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Exhibit 99.1 furnished under Regulation FD, but excluded from Section 18 “filed” status.
Cytek Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, but excluded from Section 18 “filed” status
- Information generally not incorporated into other Securities Act or Exchange Act filings by reference
- Investor impact depends on substantive Exhibit 99.1 disclosure, which is not included here
Item 8.01 · Other Events
- Jury verdict favored Cytek on three of four asserted Beckman Coulter patent claims
- $20 million lost-profit award and $36.11 million royalty award for one claim
- Cytek plans post-verdict motions challenging doctrine-of-equivalents infringement and damages
- Potential appeal and ongoing royalty obligations create additional financial and operating uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cytek Biosciences, Inc. 8-K filings
Get the next CTKB 8-K as it lands
Follow CTKB for push alerts, or ask the research agent what this filing means.